Researchers have developed an electrochemical sensor that can detect pancreatic cancer in its early stages. The device offers a simpler, more affordable alternative to conventional tests, which are less accessible.
A 3D brain marker may help identify which patients with idiopathic normal pressure hydrocephalus (iNPH) benefit from shunt surgery – improving outcomes and sparing others from ineffective treatment.
Not all precancerous lesions will develop into tumours, yet the majority are treated as if they were already breast cancer. A new marker could help identify the relevant cases and avoid overtreatment.
A multidisciplinary team of pathologists, oncologists and biologists has discovered a new biomarker to determine whether immunotherapy may work in people with colon and rectal cancer.
Researchers have developed a new MRI-based method that enables objective quantification of the growth of the most aggressive brain tumours, particularly glioblastoma.
A biomarker discovered in the cerebrospinal fluid could improve diagnosis of Parkinson's disease and dementia with Lewy bodies.
Siemens Healthineers has announced the availability of two blood-based biomarker tests for research use: the Atellica IM Phosphorylated tau 217 (pTau217) and the Atellica IM Brain Derived Tau (BDTau) assays. Both are run on the Atellica Solution IM and Atellica CI Analyzers.
To better distinguish between healthy and diseased gut microbiomes, scientists have created an index that tracks microbial behavior and signals conditions such as colorectal cancer.
Advances in artificial intelligence and multimodal data integration are poised to revolutionise cancer diagnostics – but significant challenges remain before these technologies can be routinely deployed in clinical practice. Professor Manuel Salto-Tellez outlined the steps needed to bridge the gap between complex tumour biology and the relatively simple biomarkers currently available, speaking…
Researchers report on decisive steps towards an early diagnosis of Parkinson’s disease: a newly discovered biomarker in the blood could open a window of opportunity for future treatment.
A new study into the long-term health impacts of coronavirus has found changes in the blood after Covid-19 that might pinpoint patients at risk of ongoing lung disease.
An international study shows that Alzheimer’s disease biomarkers can be accurately detected using simple finger-prick blood samples that can be collected at home and mailed to a laboratory.
A new University of Toronto-led study has discovered a possible biomarker linked to multiple sclerosis (MS) disease progression that could help identify patients most likely to benefit from new drugs.
A simple blood test that can very accurately predict the chance of survival with good recovery could be of great significance for patients in intensive care after a cardiac arrest.
Even minor functional impairments of the kidneys can have serious consequences for patients after major surgery. New biomarkers could help identify high-risk patients at an early stage.
Depression is not only a disease of the mind or the brain, a new study finds: a research team has revealed deep connections to abnormalities in the body's overall immune response.
Biomarker testing is ushering in a novel era of therapy personalisation for gastroesophageal and colorectal cancers, according to experts presenting at the 37th European Congress of Pathology in Vienna this September. During a session on state-of-the-art in gastrointestinal biomarkers, speakers outlined how targeted therapies and immunotherapies are transforming treatment options – but…
Newly discovered blood biomarkers may offer new options to track Duchenne muscular dystrophy (DMD) in a less invasive way than physical tests or biopsies. This could support more tailored treatments.
Chronic fatigue (ME/CFS) affects millions worldwide, but is poorly understood and has long lacked reliable diagnostic tools. Now, a new blood test claims to diagnose the condition with 96% accuracy.
